Handl Therapeutics (handltherapeutics.com) has been awarded a €3 million research grant from Flanders Innovation & Entrepreneurship (VLAIO) to enable accelerated development of its first gene therapy program.
Handl Therapeutics is a rapidly growing and transformative gene therapy company developing a new generation of gene therapy technologies, designed to produce superior therapeutic programs for the treatment of neurodegenerative diseases.
Handl Therapeutics is developing multiple therapeutic adeno associated virus (AAV) based programs in collaboration with the Katholieke Universiteit Leuven, with the Center for Applied Medical Research (CIMA) of the University of Navarra, Spain, and with the Biomedical Neuroscience Institute (BNI) of the University of Chile.
The Company is currently conducting IND-enabling preclinical studies.
Florent Gros, Chief Executive Officer, commented, “We are pleased that VLAIO has recognised our breakthrough science that will enable us to discover and develop therapeutic programs aiming to transform the lives of patients with neurodegenerative diseases.”
Michael Linden, Chief Scientific Officer, added, “We are thrilled that our vision has been recognized by this important Flemish funding body. We are well positioned to aggressively push our ambitious goal to develop potentially transformative treatments for these devastating diseases.”
About Handl Therapeutics
The vision of Handl Therapeutics is to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases, which represent significant unmet medical needs in healthcare. The company’s business model is based on a highly integrated approach that is built on tight links with an international network of academic partners. This allows Handl Therapeutics’ to operate a streamlined business that is designed to deliver transformative advanced medicines to the market.
Handl Therapeutics was founded in 2019 and is based at the Bio-Incubator in Leuven, Belgium. www.handltherapeutics.com